Skip to main content

Table 3 Blood sampling schedule for study arms 1, 2, 3

From: The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial

  Visit 4 Visit 5 - 1 day after Visit 6 - 3 days after (+1 day) Visit 7 - 1 week after (±2 days) Visit 8 - 15 days after (+2 days) Visit 9 - 1 month after (±5 days) Visit 10 - 6 months after (±14 days)
  Pre-vaccination (any time before dosing) Post-vaccination (1 hour)
Physical examination   × × × × x × ×
Vital signsa × × × × × x × ×
Assessment for clinical symptoms (local and general symptoms)   × × × × x   
Blood sampling in relation to YF17D vaccination ×   × × ×   × ×
Adverse eventsb ×   × × × x × ×
Concomitant medications ×   × × × x × ×
  1. aVital signs include temperature (oral and tympanic allowed), blood pressure, pulse rate, and respiratory rate. bClinical Trial Certificate Adverse Events version 4.0 will be used for grading. YF, yellow fever.